GRAIL, LLC
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The compan… Read more
GRAIL, LLC - Asset Resilience Ratio
GRAIL, LLC (GRAL) has an Asset Resilience Ratio of 22.41% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how GRAIL, LLC's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down GRAIL, LLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $654.70 Million | 22.41% |
| Total Liquid Assets | $654.70 Million | 22.41% |
Asset Resilience Insights
- Good Liquidity Position: GRAIL, LLC maintains a healthy 22.41% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
GRAIL, LLC Industry Peers by Asset Resilience Ratio
Compare GRAIL, LLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for GRAIL, LLC (2018–2025)
The table below shows the annual Asset Resilience Ratio data for GRAIL, LLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.41% | $654.70 Million | $2.92 Billion | +4.00pp |
| 2024-12-31 | 18.41% | $549.24 Million | $2.98 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $4.56 Billion | -- |
| 2020-12-31 | 58.51% | $413.29 Million | $706.30 Million | -4.61pp |
| 2019-12-31 | 63.12% | $401.15 Million | $635.52 Million | -16.41pp |
| 2018-12-31 | 79.53% | $546.26 Million | $686.85 Million | -- |